Penumbra Reports Strong Q1 2026 Growth Amid Boston Scientific Acquisition
Event summary
- Penumbra reported $374.8M in Q1 2026 revenue, up 15.6% YoY.
- Embolization and access revenue grew 23.8% YoY, outpacing thrombectomy's 12.1% increase.
- Gross profit margin improved to 67.6%, up 1.0% from Q1 2025.
- Net income declined to $32.6M from $39.2M in Q1 2025 due to acquisition-related expenses.
- Company will not provide 2026 financial guidance due to pending acquisition by Boston Scientific.
The big picture
Penumbra's strong Q1 2026 results highlight the continued demand for its vascular intervention technologies, particularly in embolization and access products. The pending acquisition by Boston Scientific signals a strategic consolidation in the medical device sector, with implications for innovation and market competition. The deal's success will depend on seamless integration and maintaining Penumbra's growth trajectory in a competitive landscape.
What we're watching
- Integration Challenges
- How Boston Scientific will manage Penumbra's operational integration while maintaining growth momentum in key product lines.
- Regulatory Approval
- Whether the acquisition will face regulatory hurdles that could delay or complicate the transaction.
- Product Strategy
- The pace at which Penumbra's embolization and access products will continue to outperform its core thrombectomy business.
Related topics